Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Bio2 Technologies is raising $4,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Thomas Afzal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bio2 Technologies

Vitrium is the first biomaterial with sufficient strength to be used in spine reconstruction while stimulating the complete substitution of the implant with the patient’s own remodeled bone. Humans replace a significant amount of their bone tissue every year through a continuous process of regeneration. Vitrium stimulates this same natural biologic process producing new bone tissue. Vitrium is strong enough to be used in load bearing applications such as spinal fusion, while maintaining sufficient strength, it is replaced with new bone. Vitrium is composed of fibers made of bioactive glass, a unique material with decades of research supported by a long history of safe clinical use.

To learn more about Bio2 Technologies, visit http://www.bio2tech.com/

Contact:
Thomas Afzal, President and Chief Executive Officer
781-569-0559

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved